Sites in India, China, Hong Kong, and Kenya are being considered. Spigelman stated that moxifloxacin has shown an excellent safety profile and has proven highly effective in clearing TB in four months during phase II trials. Part of the new trial will be to determine whether the drug cures TB faster when it is substituted for existing drugs ethambutol or isoniazid, rather than adding it to the present TB treatment regimen. He noted that the $20 million cost would be funded by the Global TB Alliance and the Bill and Melinda Gates Foundation. The following three sites in India are reported to be under consideration as testing sites for the clinical trial: Christian Medical College, Vellore; TB Research Center, Chennai; and the National TB Institute, Bangalore. The study will be a double-blind, randomized, placebo controlled study.

The number of cases of multidrug-resistant TB rose from 23 to 39 over the same time period. The study, which was published in the British Medical Journal, attributes the increase in resistance to the drug isoniazid to immigration of many TB patients from sub-Saharan Africa and the Indian subcontinent. Michelle Kruijshaar, who led the study, noted that the increases highlight the need for early case detection, rapid testing of drug susceptibility, and improved treatment completion.